Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Bicycle Therapeutics (BCYC) stocks in Canada
Learn how to easily invest in Bicycle Therapeutics stocks.
Bicycle Therapeutics is a biotechnology business based in the US. Bicycle Therapeutics stocks (BCYC.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $31.02 – a decrease of 0.64% over the previous week. Bicycle Therapeutics employs 109 staff and has a trailing 12-month revenue of around $11.8 million.
How to buy shares in Bicycle Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – BCYC – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
- Can I buy shares in Bicycle Therapeutics?
- Has coronavirus impacted Bicycle Therapeutics shares?
- Bicycle Therapeutics shares summary
- Compare share dealing platforms
- Is Bicycle Therapeutics stock a buy or sell?
- Bicycle Therapeutics performance over time
- Bicycle Therapeutics's financials
- How volatile are Bicycle Therapeutics shares?
- Does Bicycle Therapeutics pay a dividend?
- Other common questions
Bicycle Therapeutics stock price (NASDAQ:BCYC)Use our graph to track the performance of BCYC stocks over time.
Bicycle Therapeutics shares at a glance
|Latest market close||$46.33|
|52-week range||$20.67 - $62.08|
|50-day moving average||$54.57|
|200-day moving average||$41.23|
|Wall St. target price||$73.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.87|
Compare online stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Is it a good time to buy Bicycle Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Bicycle Therapeutics price performance over time
|1 week (2022-01-19)||-0.64%|
|1 month (2021-12-23)||-23.13%|
|3 months (2021-10-26)||-13.77%|
|6 months (2021-07-26)||34.45%|
|1 year (2021-01-26)||72.68%|
|2 years (2020-01-24)||330.98%|
|3 years (2019-01-22)||N/A|
|5 years (2017-01-22)||N/A|
Bicycle Therapeutics financials
|Revenue TTM||$11.8 million|
|Gross profit TTM||$-22,759,000|
|Return on assets TTM||-17.9%|
|Return on equity TTM||-47.23%|
|Market capitalisation||$1.4 billion|
TTM: trailing 12 months
Bicycle Therapeutics share dividends
We're not expecting Bicycle Therapeutics to pay a dividend over the next 12 months.
Bicycle Therapeutics share price volatility
Over the last 12 months, Bicycle Therapeutics's shares have ranged in value from as little as $20.6701 up to $62.075. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bicycle Therapeutics's is -0.2565. This would suggest that Bicycle Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Bicycle Therapeutics has bucked the trend.
Bicycle Therapeutics overview
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase I clinical trials for the treatment of diabetic macular edema. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Bicycle Therapeutics in the news
Earnings playbook: A complete guide to this week's reports, including the first of tech
Markets are expected to remain on edge as the Fed meets in the week ahead
HighMark Wealth Management LLC Buys iShares Russell 2000 ETF, SeaSpine Holdings Corp, Model N ...
Frequently asked questions
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.
More guides on Finder
How to buy Haemonetics Corporation stock in Canada
Steps to owning and managing HAE stock, with 24-hour and historical pricing before you buy.
Go Auto Review
Use Go Auto to shop for new or used vehicles from multiple dealerships, with no hidden fees and access to bad credit financing.
How to buy Aritzia stock in Canada
Steps to owning and managing Aritzia (ATZ) stock, with 24-hour and historical pricing before you buy.
CI Direct Trading review
Get low fees and access many different types of accounts, platforms and investments with this reputable online broker.
Hifi Finance (MFT) price prediction
Read our expert analysis on Hifi Finance and how the token will perform in the future.
Kusama (KSM) price prediction
Read our expert analysis on Kusama and how the token will perform in the future.
How to buy The Sandbox (SAND) in Canada
This guide provides step-by-step instructions on how to buy The Sandbox, lists some exchanges where you can get it and provides daily price data on SAND.
COVID testing stocks
We’ve rounded up stats on some of the most popular COVID testing stocks, along with information on how they compare and how to invest.
Shiba Inu (SHIB) price, history and performance
This guide explores the different ways of buying Shiba Inu on a cryptocurrency exchange as well as where you should store your cryptocurrency.
Baby Doge Coin (BABYDOGE) price, chart, coin profile and news
This guide provides step-by-step instructions on how to buy Baby Doge Coin, lists some exchanges where you can get it and provides daily price data on BABYDOGE.